SCHEMBL7608888

SCHEMBL7608888

COc1ccccc1N(CC=O)C(=O)C1CCCCC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.47
KMT2A Q03164 5/20 0.45
HTR1A P08908 3/20 0.45
DRD4 P21917 3/20 0.45
ADRA1D P25100 3/20 0.45
ADRA1A P35348 3/20 0.45
ADRA1B P35368 3/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
TSHR P16473 1/20 0.45
HTR1B P28222 1/20 0.45
HTR7 P34969 1/20 0.45
HTR2B P41595 1/20 0.44
MEN1 O00255 4/20 0.43
LMNA P02545 1/20 0.43
BLM P54132 1/20 0.43
PMP22 Q01453 1/20 0.43
NR1H4 Q96RI1 1/20 0.43
HPGD P15428 3/20 0.42
MAPT P10636 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7609692 0.84 NR1H4 (0.39) SMN1; SMN2HTR1ADRD4ADRA1DADRA1A
SCHEMBL8296928 0.83 LMNA (0.42) SMN1; SMN2KMT2AMEN1LMNAMAPT
SCHEMBL7613414 0.82 SMN1; SMN2 (0.45) SMN1; SMN2KMT2AHTR1ADRD4ADRA1D
SCHEMBL29138505 0.79 PAX8 (0.43) SMN1; SMN2LMNABLM
SCHEMBL8303697 0.76 HTT (0.61) SMN1; SMN2KMT2AHTR1ADRD4ADRA1A
SCHEMBL6933222 0.75 HTR1A (0.78) SMN1; SMN2KMT2AHTR1ADRD4ADRA1D
SCHEMBL8303076 0.71 CNR2 (0.45) SMN1; SMN2LMNANR1H4MAPTTP53
SCHEMBL6546816 0.71 SMN1; SMN2 (0.70) SMN1; SMN2KMT2AHTR1ADRD4ADRA1D
SCHEMBL7607082 0.71 SMN1; SMN2 (0.40) SMN1; SMN2KMT2AHTR1ADRD4ADRA1D
SCHEMBL3035511 0.70 ACHE (0.46) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020193383-A1 1-(N-phenylalkylaminoalkyl)piperazine derivatives substituted at position 2 of the phenyl ring RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMOANY 2002-12-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193383-A1 1-(N-phenylalkylaminoalkyl)piperazine derivatives substituted at position 2 of the phenyl ring NLN, GLS, CPT1B SMN1; SMN2 7/4885KMT2A 3995/4885HTR1A 1328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.